NEW YORK, July 19, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/acad.
The investigation concerns whether Acadia and certain of its officers and/or directors have violated federal securities laws.
On April 9, 2018, CNN published an article that questioned whether Acadia's Nuplazid treatment may have caused the deaths of sick and elderly patients. Following this news Acadia stock dropped $5.03 per share or over 23% to close at $16.50 on April 9, 2018. Then, on July 9, 2018, The Southern Investigative Reporting Foundation reported that that Acadia's "pursuit of regulatory approval is best described as 'loophole-centric.'" Following this news Acadia stock dropped $1.21 per share or over 6.7% to close at $16.63 on July 9, 2018.
If you are aware of any facts relating to this investigation, or purchased Acadia shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/acad. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | firstname.lastname@example.org
SOURCE Bronstein, Gewirtz & Grossman, LLC